Seqirus Begins Shipping 2018-2019 Influenza Vaccines to the U.S. Market
SUMMIT, N.J: Seqirus announced it has begun shipping its portfolio of seasonal influenza vaccines to customers in the United States for the 2018-2019 influenza season.
The company will provide FLUAD (Influenza Vaccine, Adjuvanted), the only adjuvanted seasonal influenza vaccine specifically developed for people aged 65 and older1; and FLUCELVAX QUADRIVALENT (Influenza Vaccine), the most widely available cell-based influenza vaccine in the country, available for those aged four and older. Ongoing manufacturing innovations have enabled Seqirus, the largest producer of cell-based influenza vaccines in the U.S., to continue to boost production of FLUCELVAX QUADRIVALENT. Almost half of the total doses supplied by the company in the U.S. this season will be FLUCELVAX QUADRIVALENT.
The Seqirus 2018-2019 influenza vaccine portfolio also includes AFLURIA QUADRIVALENT (Influenza Vaccine), an egg-based quadrivalent influenza vaccine. Seqirus also distributes Rapivab (peramivir injection), the first-and-only one-dose intravenous antiviral treatment for acute uncomplicated influenza.3-5
The complete portfolio of influenza vaccines provides a range of options for children aged 4 years to people aged 65 years and older, presented in pre-filled syringes as well as multi-dose vials.6-8
Seqirus produces influenza vaccines across its global manufacturing network, which includes a state-of-the-art plant in Holly Springs, North Carolina. This facility utilizes the latest cell-culture technology and was built in partnership with the U.S. government to support pandemic preparedness and emergency response.9
"As the only global vaccine company solely dedicated to the prevention of influenza, Seqirus is committed to partnering with healthcare professionals on the front line of influenza prevention to provide the broadest range of vaccine options as early as possible. We are pleased to build on our track record of early and reliable supply by being one of the first influenza vaccine manufacturers to ship product to the U.S. market during this influenza season," said Brent MacGregor, Senior Vice President, Commercial Operations at Seqirus.
"Millions of people - particularly those 65 and older, children, and anyone with an underlying medical condition, such as asthma, heart disease, or diabetes, are at increased risk from influenza and its associated complications. According to the CDC, the best way to prevent the flu is by getting vaccinated each year," said Gregg Sylvester MD, Vice President of Medical Affairs at Seqirus.